News Detail

This Charles Schwab Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Benzinga · 04/02 14:31

Listen to the news

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

HC Wainwright & Co. analyst Mitchell Kapoor upgraded the rating for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) from Sell to Neutral and maintained the price target of $75. Sarepta Therapeutics shares closed at $61.91 on Tuesday. See how other analysts view this stock.
JP Morgan analyst Jimmy Bhullar upgraded Reinsurance Group of America, Incorporated (NYSE:RGA) from Neutral to Overweight and raised the price target from $232 to $237. Reinsurance Group shares closed at $198.27 on Tuesday. See how other analysts view this stock.
Citigroup analyst Christopher Allen upgraded the rating for The Charles Schwab Corporation (NYSE:SCHW) from Neutral to Buy and lifted the price target from $85 to $102. Charles Schwab shares closed at $77.67 on Tuesday. See how other analysts view this stock.
Goldman Sachs analyst Will Nance upgraded Fiserv, Inc. (NYSE:FI) from Neutral to Buy and raised the price target from $246 to $260. Fiserv shares closed at $222.01 on Tuesday. See how other analysts view this stock.
Truist Securities analyst Bill Chappell upgraded The Scotts Miracle-Gro Company (NYSE:SMG) from Hold to Buy and maintained the price target of $70. Scotts Miracle Gro shares closed at $54.77 on Tuesday. See how other analysts view this stock.

Considering buying SCHW stock? Here’s what analysts think:

Read This Next:

How To Earn $500 A Month From Conagra Brands Stock Ahead Of Q3 Earnings

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.